{"id":"a69373bf-e968-5e1a-bfd0-1571c38bffc5","stable_key":"00c24cfe-6189-5244-b81f-5d693e4e177d:chlorogenic_acid-liver-stiffness-null","predicate":"was_not_superior_to_placebo_for","statement":"CGA did not outperform placebo for liver stiffness.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"context_dependent","is_public":true,"mechanism_event_id":"71f6701a-a568-5ddc-b5e6-aa55644a00c1","mechanism_event_label":"A separate fibrosis-related measurement was also null.","subject":{"id":"705c7f84-5840-55e1-be69-383cc8793a06","slug":"chlorogenic-acid","display_name":"Chlorogenic acid / 5-O-caffeoylquinic acid","entity_type_key":"small_molecule"},"object":{"id":"77690ebd-8f3b-5de3-a95f-15bba654543f","slug":"liver-stiffness","display_name":"Liver stiffness measured by elastography","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"71f6701a-a568-5ddc-b5e6-aa55644a00c1","stable_key":"00c24cfe-6189-5244-b81f-5d693e4e177d:chlorogenic_acid-liver-stiffness-null-event","event_type":"observed_intervention","label":"A separate fibrosis-related measurement was also null.","description":"CGA did not outperform placebo for liver stiffness.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"705c7f84-5840-55e1-be69-383cc8793a06","slug":"chlorogenic-acid","display_name":"Chlorogenic acid / 5-O-caffeoylquinic acid","entity_type_key":"small_molecule"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"77690ebd-8f3b-5de3-a95f-15bba654543f","slug":"liver-stiffness","display_name":"Liver stiffness measured by elastography","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/chlorogenic_acid-research/33838673.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"749cbe05e73aeb9c4a69c8c00e8a3839241f343b5c0eb9662b64f4127506f319\", \"start_char\": 0, \"end_char\": 2205, \"text_sha256\": \"749cbe05e73aeb9c4a69c8c00e8a3839241f343b5c0eb9662b64f4127506f319\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Six-month double-blind randomized four-arm trial","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Daily 200 mg CGA, 200 mg caffeine, both, or starch placebo","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Chronic human liver disease differs from surgical mouse regeneration. The trial does not isolate all possible formulations, but its null hepatic result must remain visible.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Chlorogenic acid research collection; topical membership is not evidence of a direct dietary effect.","comparator":null,"unit":null,"notes":"","entity":{"slug":"chlorogenic-acid","display_name":"Chlorogenic acid / 5-O-caffeoylquinic acid","entity_type_key":"small_molecule"}},{"dimension":"organism","value_text":"Human participants with type 2 diabetes and NAFLD","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"A separate fibrosis-related measurement was also null.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[chlorogenic_acid-p33838673] Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33838673/ DOI: 10.1186/s12937-021-00694-5","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"FibroScan, hepatic blood tests, metabolic and inflammatory markers","comparator":null,"unit":null,"notes":"","entity":null}],"evidence":[{"id":"5233156b-2c67-5bcb-817f-9ee994c22924","evidence_kind":"source_excerpt","locator":"Lines 1049-1060","start_line":1049,"end_line":1060,"excerpt":"### chlorogenic_acid-liver-stiffness-null\nCGA did not outperform placebo for liver stiffness.\nCondition category: normal\nnutrient_topic: Chlorogenic acid research collection; topical membership is not evidence of a direct dietary effect.\nplain_language: A separate fibrosis-related measurement was also null.\norganism: Human participants with type 2 diabetes and NAFLD\ntissue_or_cell_type: FibroScan, hepatic blood tests, metabolic and inflammatory markers\nexperimental_model: Six-month double-blind randomized four-arm trial\nlimitations: Chronic human liver disease differs from surgical mouse regeneration. The trial does not isolate all possible formulations, but its null hepatic result must remain visible.\nexposure: Daily 200 mg CGA, 200 mg caffeine, both, or starch placebo\nevidence_span: {\"source_cache\": \"artifacts/chlorogenic_acid-research/33838673.abstract.txt\", \"locator\": \"Primary indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"749cbe05e73aeb9c4a69c8c00e8a3839241f343b5c0eb9662b64f4127506f319\", \"start_char\": 0, \"end_char\": 2205, \"text_sha256\": \"749cbe05e73aeb9c4a69c8c00e8a3839241f343b5c0eb9662b64f4127506f319\"}\n[chlorogenic_acid-p33838673] Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33838673/ DOI: 10.1186/s12937-021-00694-5","model_system":"Six-month double-blind randomized four-arm trial","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [chlorogenic_acid-p33838673] Effects of supplementation with main coffee components including caffeine and/or chlorogenic acid on hepatic, metabolic, and inflammatory indices in patients with non-alcoholic fatty liver disease and type 2 diabetes: a randomized, double-blind, placebo-controlled, clinical trial. (2021). https://pubmed.ncbi.nlm.nih.gov/33838673/ DOI: 10.1186/s12937-021-00694-5","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"98a7cb8d-1d80-5cfe-9690-4068d21878e3","stable_key":"import-00c24cfe-6189-5244-b81f-5d693e4e177d","title":"Chlorogenic acid: metabolism, signaling and nutrient connections (2026-09-17)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"dabd56b55fb10d82913b222343d9592d3baf61ef3cc81cf47f3e3e7537eb7992","revision_id":"340aee2f-52a6-56aa-99c1-0a24c534752a","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}